Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.
View all episodes
